Esophageal carcinoma (squamous + adeno) · line 2 · Pembrolizumab monotherapy — 2L esophageal PD-L1 CPS ≥10 (KEYNOTE-181)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	aggressive
Linked regimen	`REG-PEMBRO-MONO-ESOPH-2L`

ID	`IND-ESOPH-METASTATIC-2L-PEMBRO-CPS10`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-ESOPHAGEAL`
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025`

Notes

STUB — pending Co-Lead sign-off. Aggressive-track 2L (PD-L1 CPS ≥10 selected). UA: pembrolizumab not NSZU-reimbursed for esophageal — out-of-pocket / charitable.

Used By

Actionability

BMA-PDL1-CPS-ESOPHAGEAL - PD-L1 CPS used as eligibility threshold for ICI in metastatic esophageal cancer. Esophage...

Algorithms

ALGO-ESOPH-2L - ALGO-ESOPH-2L

Indication

IND-ESOPH-METASTATIC-2L-NIVO-SQUAMOUS - IND-ESOPH-METASTATIC-2L-NIVO-SQUAMOUS